"Overall mortality, cardiovascular event rates, prostate cancer, lower urinary tract symptom scores, and systolic and diastolic blood pressure did not differ among testos- terone- and placebo-treated men (2)." This quote comes from the Endocrine Society's guidelines on testosterone therapy. What accounts for the discrepancy in results of previous trials to the new trials? Hx of CAD? not enough enrollees with CAD in the earlier trials? perhaps they were excluded?
Endocrine Society Offers Statement on Testosterone Therapy After Recent Reports — Physician’s First Watch
Endocrine Society Offers Statement on Testosterone Therapy After Recent Reports
By the Editors
In the wake of recent studies pointing to increased risks for cardiovascular events after testosterone therapy, the Endocrine Society has issued a statement, dated February 7, that concludes: "Large scale, prospective, randomized controlled trials are needed to determine the risks and benefits of testosterone therapy in older men with age-related decline in testosterone levels."
Until that evidence is available, the Society says, "Patients should be made aware of the potential risk of cardiovascular events in middle-aged and older men who are taking or considering testosterone therapy. ... Physicians and patients should have a conversation about the risks and benefits ... especially in patients who have pre-existing heart disease."
The statement recommends that any prescriptions for testosterone be given in accordance with the Society's practice guidelines (see link below).